Gene · 2693
Papers3,015
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,015
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs. | J Enzyme Inhib Med Chem | 2026 | 41601150 | PubTator, text mining | PubMed |
| Olfactory inputs to appetite neurons in the hypothalamus. | Proc Natl Acad Sci U S A | 2026 | 41591908 | PubTator, text mining | PubMed |
| Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. | Curr Obes Rep | 2026 | 41575482 | PubTator, text mining | PubMed |
| Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions. | Chirality | 2026 | 41555539 | PubTator, text mining | PubMed |
| Driving innovation in cancer symptom science through translational research: bridging science and practice. | Curr Opin Support Palliat Care | 2026 | 41549852 | PubTator, text mining | PubMed |
| A randomized controlled trial evaluating the effects of anamorelin in postoperative patients with upper gastrointestinal cancer: protocol for the CLEAR-UP study. | Jpn J Clin Oncol | 2026 | 41543044 | PubTator, text mining | PubMed |
| Cancer cachexia: molecular basis and therapeutic advances. | Signal Transduct Target Ther | 2026 | 41526343 | PubTator, text mining | PubMed |
Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the growth hormone secretagogue receptor blocker PF-5190457 in recently abstinent patients with alcohol use disorder. | Int J Neuropsychopharmacol | 2026 | 41474196 | PubTator, text mining | PubMed |
| LEAP2 as a therapeutic target in obesity and cardiometabolic disorders. | Rev Endocr Metab Disord | 2026 | 41284160 | PubTator, text mining | PubMed |
| The ghrelin receptor agonist AC01 improves cardiomyocyte contractility through Gαi signalling and without Ca2+ mobilization. | Cardiovasc Res | 2026 | 41206722 | PubTator, text mining | PubMed |
| Severe congenital hyperinsulinism with progressive neurological deterioration due to novel HADH-GHSR digenic mutations: the first case report. | Pediatr Endocrinol Diabetes Metab | 2025 | 41693194 | PubTator, text mining | PubMed |
| New directions in growth hormone treatment in children. | Pediatr Endocrinol Diabetes Metab | 2025 | 41693185 | PubTator, text mining | PubMed |
| Elevated blood levels of liver-expressed antimicrobial peptide 2 in patients with insulinoma and its expression in insulinomas. | Front Endocrinol (Lausanne) | 2025 | 41488138 | PubTator, text mining | PubMed |
| scHLens: a web server for hierarchically and interactively exploring single cell RNA-seq data. | Brief Bioinform | 2025 | 41403052 | PubTator, text mining | PubMed |
| Growth hormone treatment outcomes in children with genetic isolated growth hormone deficiency. | Eur J Pediatr | 2025 | 41326671 | PubTator, text mining | PubMed |
Effect of Non-surgical Periodontal Therapy on Levels of Ghrelin and Tumor Necrosis Factor-Alpha (TNF-α) in the Gingival Crevicular Fluid of Healthy and Periodontitis Patients With and Without Type 2 Diabetes Mellitus: A Clinico-Biochemical Study. | Cureus | 2025 | 41280962 | PubTator, text mining | PubMed |
| Serum LEAP-2 as a Potential Biomarker for Hepatic Steatosis in Adolescents with Obesity and MASLD: A Cross-Sectional Study. | Diagnostics (Basel) | 2025 | 41226108 | PubTator, text mining | PubMed |
| Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years? | Expert Opin Investig Drugs | 2025 | 41222020 | PubTator, text mining | PubMed |
| Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial. | EClinicalMedicine | 2025 | 41181834 | PubTator, text mining | PubMed |
| Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response. | In Vivo | 2025 | 41167673 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2693/papers?page=3